ER、PR以及Ki-67状态与乳腺癌新辅助化疗疗效的相关性  

Correlation of ER,PR,and Ki-67 status with the efficacy of neoadjuvant chemotherapy for breast cancer

作　　者：邓丁梅[1] 叶娴 温润耀 张玉娟[1] 叶建森 DENG Dingmei;YE Xian;WEN Runyao;ZHANG Yujuan;YE Jiansen(Department of Mammary Gland,Dongguan People's Hospital,Dongguan,Guangdong,China,523000)

机构地区：[1]广东省东莞市东莞市人民医院乳腺科,广东东莞523000

出　　处：《分子诊断与治疗杂志》2021年第1期83-86,90,共5页Journal of Molecular Diagnostics and Therapy

基　　金：广东省医学科学技术研究基金项目(A2018195)。

摘　　要：目的探究雌激素受体(ER)、孕激素受体(PR)以及Ki67抗原(Ki67)状态与乳腺癌(BC)新辅助化疗疗效的相关性。方法选取本院2015年12月至2020年5月216例乳腺癌患者,术前均进行新辅助化疗。采用免疫组织化学染色检测ER、PR、Ki-67,评价疗效,分析ER、PR、Ki-67与疗效的关系。结果总有效率为87.04%(188/216),病理完全缓解(pCR)为15.74%(34/216)。化疗后ER阳性率、PR阴性率增加,与化疗前相比,差异无统计学意义(P>0.05)。化疗后Ki-67阴性率显著高于化疗前,差异有统计学意义(P<0.05)。ER、PR、Ki-67状态与新辅助化疗治疗疗效均无显著相关性(P>0.05,r=0.632)。ER阴性表达是预测新辅助化疗疗效pCR的独立因素,差异有统计学意义(P<0.05)。结论PR、Ki-67状态与乳腺癌新辅助化疗疗效无明显的联系,ER与其呈负相关。Objective To explore the correlation between estrogen receptor(ER),progesterone receptor(PR)and Ki67 antigen(Ki67 antigen,Ki67)status and the efficacy of neoadjuvant chemotherapy for breast cancer(BC).Methods From December 2015 to May 2020 in our hospital,216 breast cancer patients received neoadjuvant chemotherapy before surgery.Immunohistochemical staining was used to detect ER,PR,Ki-67;evaluate the efficacy;analyze the relationship between ER,PR,Ki-67 and the efficacy.Results The total effective rate was 87.04%(188/216),and the pathologic complete response(pCR)was 15.74%(34/216).The positive rate of ER and negative rate of PR increased after chemotherapy,and the difference was not statistically significant compared with before chemotherapy(P>0.05).The Ki-67 negative rate after chemotherapy was significantly higher than before chemotherapy,and the difference was statistically significant(P<0.05).There was no significant correlation between ER,PR,Ki-67 status and the efficacy of neoadjuvant chemotherapy(all P>0.05,r=0.632).The negative expression of ER was an independent factor predicting the pCR of neoadjuvant chemotherapy,and the difference was statistically significant(P<0.05).Conclusion There is no obvious relationship between PR and Ki-67 status and the efficacy of neoadjuvant chemotherapy for breast cancer.ER was negatively correlated with the efficacy of neoadjuvant chemotherapy.

关 键 词：新辅助化疗 乳腺癌 KI67抗原 孕激素受体 雌激素受体 相关性分析 

分 类 号：R737.9[医药卫生—肿瘤]